Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15618230 | 0.78 | SLC6A4 (0.48) | SLC6A4HRH3SLC6A2HTR2AHRH1 | |
| SCHEMBL15618267 | 0.75 | MAPT (0.48) | SLC6A4HRH3 | |
| SCHEMBL11236550 | 0.75 | SLC6A4 (0.56) | SLC6A4HRH3SLC6A2HTR2AHRH1 | |
| SCHEMBL11226530 | 0.72 | SLC6A4 (0.49) | SLC6A4HRH3SLC6A2HTR2AHRH1 | |
| SCHEMBL11709823 | 0.72 | ALDH1A1 (0.42) | — | |
| SCHEMBL7158810 | 0.71 | SLC6A4 (0.73) | SLC6A4HRH3SLC6A2HTR2AHRH1 | |
| SCHEMBL15618262 | 0.71 | UTS2R (0.44) | SLC6A4HRH3 | |
| SCHEMBL15618236 | 0.69 | SLC6A4 (0.49) | SLC6A4HRH3SLC6A2HTR2AHRH1 | |
| SCHEMBL11710902 | 0.69 | MIF (0.44) | SLC6A2 | |
| SCHEMBL5270870 | 0.69 | SLC6A4 (0.70) | SLC6A4HRH3SLC6A2HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014046544-A1 | SUBSTITUTED 3-HETEROARYLOXY-3-(HETERO)ARYL-PROPYLAMINES AS SEROTONIN TRANSPORTER AND SEROTONIN HT2C RECEPTOR MODULATORS | AAPA B.V. (NL) | 2014-03-27 | — | — | WO | disclosed |
| US-20100113606-A1 | AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113606-A1 | AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR | ADRB1, ADRB2, ADRB3 | SLC6A4 629/4885HRH3 380/4885SLC6A2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.